Journals / Retina-Vitreus / 2016 / Cilt: 24 - Sayı: 4

The Effect of Initial Macular Thickness on Anatomic and Functional Response to Ranibizumab Treatment in Diabetic Macular Edema

Diyabetik Maküla Ödeminde İntravitreal Ranibizumab Tedavisinde Başlangıç Maküla Kalınlığının Anatomik ve Fonksiyonel Cevaba Etkisi

Pages
323–326
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In cases with high macular thickness, successful anatomic results can be obtained.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effect of initial central foveal thickness (CFT) on the anatomical and visual prognosis on intravitreal ranibizumab treatment for diabetic macular edema (DME).Materials and Methods: Patients received intravitreal ranibizumab treatment for DME and having follow-up at least 6 months were evaluated.
📊
Key Findings & Data:The demographic features, the CFT and best corrected visual acuity (BCVA) initially, at 3 month, at 6 month and at last follow up was recorded.
💡
Conclusion & Impact:In cases with high macular thickness, successful anatomic results can be obtained.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the effect of initial central foveal thickness (CFT) on the anatomical and visual prognosis on intravitreal ranibizumab treatment for diabetic macular edema (DME).Materials and Methods: Patients received intravitreal ranibizumab treatment for DME and having follow-up at least 6 months were evaluated. The demographic features, the CFT and best corrected visual acuity (BCVA) initially, at 3 month, at 6 month and at last follow up was recorded. The cases having CFT less than 400 µm (group 1) and having CFT 400 µm and more (group 2) were compared according to anatomical and functional outcomes. Results: The mean follow up period of 35 eyes in group 1 and 47 eyes in group 2 was 16.49±7.58 months. The CFT initially, at 3 month, at 6 month and at last follow up in group 1 was 345.06±44.38 µm, 299.14±78.8 µm, 315.83±98.6 µm, 277.47±85 µm and in group 2, 510.23±85.16 µm, 368.64±138.4 µm, 380.30±145.1 µm and 322.23±134.15 mm respectively. There was no statistical significant difference between groups at last follow up. The BCVA initially, at 3 month, at 6 month and at last follow up in group 1 was 0.63±0.47 logMar, 0.5±0.5 logMar, 0.38±0.43 logMar, 0.36±0.48 logMar and in group 2, 0.72±0.4 logMar, 0.58±0.5 logMar, 0.58±0.5 logMar and 0.55±0.42 logMar respectively. The difference between groups at last follow up was statistical significant. Conclusion: The beginning CFT may be a factor affecting adversely the visual prognosis. In cases with high macular thickness, successful anatomic results can be obtained.

Özet

Amaç: Diyabetik maküla ödeminde (DMÖ) intravitreal ranibizumab tedavisinde tedavi öncesi santral fovea kalınlığının (SFK) anatomik ve görsel prognoz üzerine etkisinin araştırılması. Gereç ve Yöntem: Diyabetik maküla ödemi nedeni ile intravitreal ranibizumab tedavisi uygulanan ve en az 6 ay takibi bulunan olgular incelendi. Olguları demografik özelliklerine göre incelendi ve tedavi öncesi, 3, 6 ay ve son takiplerindeki SFK'ları ve en iyi düzeltilmiş görme keskinlikleri (EDGK) kaydedildi. Santral fovea kalınlığı 400 mm altında olan (grup 1) ve 400 µm ve üzerinde olan (grup 2) olgular anatomik ve fonksiyonel açıdan karşılaştırıldı.Bulgular: Grup 1'de 35, grup 2'de 47 gözün ortalama takip süresi 16.49±7.58 aydı. Grup 1'de olguların başlangıç, 3, 6 ay ve son takiplerindeki SFK'ları sırası ile 345.06±44.38 mm, 299.14±78.8 mm, 315.83±98.6 mm, 277.47±85 mm, grup 2'de ise 510.23±85.16 mm, 368.64±138.4 mm, 380.30±145.1 mm ve 322.23±134.15 mm idi. Gruplar arasında son takipte istatistiksel bir fark bulunmamaktaydı. Olguların EDGK'ları grup 1'de başlangıç, 3, 6 ay ve son takiplerinde sırası ile 0.63±0.47 logMar, 0.5±0.5 logMar, 0.38±0.43 logMar, 0.36±0.48 logMar, grup 2'de ise 0.72±0.4 logMar, 0.58±0.5 logMar, 0.58±0.5 logMar ve 0.55±0.42 logMar idi. Son takipte gruplar arasında istatistiksel olarak anlamlı bir fark mevcuttu. Sonuç: Başlangıç SFK, DMÖ'de görsel prognozu olumsuz etkileyen bir faktör olabilir. Maküla kalınlığı yüksek olan olgularda anatomik olarak başarılı sonuçlar alınabilmektedir.

🔖

Cite This Article

ÜNEY, G. Ö., ÜNLÜ, N., HAZIROLAN, D., ACAR, M. A., ÖRNEK, F. (2016). The Effect of Initial Macular Thickness on Anatomic and Functional Response to Ranibizumab Treatment in Diabetic Macular Edema. Retina-Vitreus, Cilt: 24 - Sayı: 4, 323–326. https://ajindex.com/articles/306927

References (14)

  1. Moss S, Klein R, Klein B. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003
  2. Fong DS, Aiello L, Gardner TW et al. Retinopathy in diabetes. Diabetes Care 2004;27:84-7
  3. Funatsu H, Yamashita H, Noma et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-7
  4. Jonas JB, Neumaier M. Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 2007;39:139-42
  5. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005;6:511-24
  6. Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33:2399-405
  7. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25
  8. Nguyen QD, Shah SM, Khwaja A et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51
  9. Diabetic Retinopathy Clinical Research Network Study Group. Optical Coherence Tomography Measurements and Analysis Methods in Optical Coherence Tomography Studies of Diabetic Macular Edema. Ophthalmology 2008;115:1366-71
  10. Writing comittee for the Diabetic Retinopathy Clinical Research Network. Comparison of the early treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmo. 2007;125:469-80
  11. Tranos PG, Wickremasinghe SS, Stangos NT et al. Macular oedema. Surv Ophthalmol 2004;49:470-90
  12. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74
  13. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
  14. Brown DM, Nguyen QD, Marcus DM et al: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. O